David Bott, Director of Innovation Programs at the Technology Strategy Board UK, presented at last year's Stem Cells USA & Regenerative Medicine Congress on the topic, â€˜Regenerative medicine: From concept to commercialization.'
In his presentation, David looks at biotech capital strategies, including government, public-private finance and entrepreneurial activities, and ways to drive innovation in regenerative medicine.
He gives an overview on:
- British Government investment in short-term feasibility studies to stimulate innovation by small companies in regenerative medicine
- The responsibility of funders: encouraging important initial feasibility work required to see if new ideas are workable
- Update on progress: who is getting funding? What results have been seen to date and how will this impact the field?
For up to date information on the stem cells and regenerative medicine market, register now for Stem Cells USA & Regenerative Medicine Congress.